Clinical trials: Dexamethasone Administration
Diabetic Macular Edema
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis®…
- Trial name
- OXEYE (NCT05697809)
- Testing
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Oxular Limited
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Acute Fungal Otitis Externa
FST-201 In The Treatment of Acute Fungal Otitis Externa
The objective of this study is to evaluate the efficacy of FST-201 compared to vehicle in the treatment of acute fungal otitis externa.
- Trial name
- NCT00945646
- Testing
- FST-201 (dexamethasone 0.1%) Otic Suspension, Vehicle
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Shire
Plasma Cell Myeloma
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Primary Objectives: Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- Trial name
- PomdeSAR (NCT02283775)
- Testing
- Isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Multiple Myeloma
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of bortezomib in participants with multiple myeloma who have previously responded to a bortezomib based therapy.
- Trial name
- NCT00431769
- Testing
- Bortezomib
- Where
- 38 sites in Austria, Belgium and 6 more
- Volunteers
- 130 people
- Sponsor
- Janssen-Cilag International NV
Inflammation and Pain Associated With Cataract Surgery
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
- Trial name
- ISV-305 (NCT03192150)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Bacterial Conjunctivitis
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.
- Trial name
- NCT03004924
- Testing
- SHP640, PVP-I 0.6%
- Where
- 163 sites in United States, Australia and 11 more
- Volunteers
- 753 people
- Sponsor
- Shire
Diabetic Macular Edema
Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)
This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).
- Trial name
- Louvre 3 (NCT03003416)
- Testing
- dexamethasone intravitreal implant
- Where
- 25 sites in France
- Volunteers
- 115 people
- Sponsor
- Allergan
Multiple Myeloma
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple…
- Trial name
- ACY-1215 (NCT01323751)
- Testing
- ACY-1215
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Celgene
Liposarcoma,Myxoid
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
The purpose of this study is to evaluate the safety and efficacy of trabectedin for the treatment of localized (non-metastatic) myxoid / round cell liposarcoma (malignant tumor derived from primitive or embryonal lipoblastic…
- Trial name
- NCT00579501
- Testing
- Trabectedin, Dexamethasone
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bacterial Vaginosis, Fungal Vaginal Infections
Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections
The purpose of this study is to evaluate the efficacy and safety of association of metronidazole, nystatin and dexamethasone in the treatment of bacterial and fungal vaginal infections.
- Trial name
- NCT02186145
- Testing
- Association of metronidazole; nystatin and dexamethasone, Flagyl
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- Marjan Industria e Comercio ltda
Dry Eye
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
- Trial name
- NCT04747977
- Testing
- OTX-DED
- Where
- 15 sites in United States
- Volunteers
- 172 people
- Sponsor
- Ocular Therapeutix, Inc.
Multiple Myeloma
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction…
- Trial name
- NCT03173092
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 21 sites in United States
- Volunteers
- 141 people
- Sponsor
- Takeda
Coronavirus Infection, Severe Acute Respiratory Infection
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive…
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NATADEX (NCT04452565)
- Testing
- Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone
- Where
- 31 sites in United States
- Volunteers
- 525 people
- Sponsor
- Biomed Industries, Inc.
Cataract
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
To assess the safety of Dextenza compared to an active control, prednisolone acetate suspension, for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.
- Trial name
- NCT04539548
- Testing
- Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- Ocular Therapeutix, Inc.
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
- Trial name
- NCT01497093
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Osteoarthritis of the Knee
Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee
This trial is a multi-site, randomized, open-label, parallel, and single-dose administration study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
- Trial name
- NCT02803307
- Testing
- TLC599
- Where
- 3 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Taiwan Liposome Company
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT03952091
- Testing
- TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
- Where
- 41 sites in China, Taiwan
- Volunteers
- 289 people
- Sponsor
- TJ Biopharma Co., Ltd.
Adrenal Insufficiency
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration
This is a single centre, open-label, randomised, single dose, three-period, crossover study to evaluate the bioavailability of Infacort® administered as 'sprinkles' with soft food and yoghurt compared with direct administration…
- Trial name
- NCT03178214
- Testing
- Infacort
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Multiple Myeloma
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy…
- Trial name
- NCT02046070
- Testing
- Cyclophosphamide, Ixazomib, Dexamethasone
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 148 people
- Sponsor
- Millennium Pharmaceuticals, Inc.